Form 8-K - Current report:
SEC Accession No. 0001104659-25-004107
Filing Date
2025-01-16
Accepted
2025-01-16 16:11:13
Documents
13
Period of Report
2025-01-10
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm253479d1_8k.htm   iXBRL 8-K 24843
  Complete submission text file 0001104659-25-004107.txt   198558

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA sls-20250110.xsd EX-101.SCH 3042
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE sls-20250110_lab.xml EX-101.LAB 34240
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE sls-20250110_pre.xml EX-101.PRE 22378
15 EXTRACTED XBRL INSTANCE DOCUMENT tm253479d1_8k_htm.xml XML 3688
Mailing Address 7 TIMES SQUARE SUITE 2503 NEW YORK NY 10036
Business Address 7 TIMES SQUARE SUITE 2503 NEW YORK NY 10036 6462005278
SELLAS Life Sciences Group, Inc. (Filer) CIK: 0001390478 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-33958 | Film No.: 25535826
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)